Targeted protein degradation (TPD) is a way to inhibit or modulate the function of disease-causing proteins that aren’t druggable using conventional small molecules. Plexium is using a proprietary high-throughput cell screening technology to explore a variety of potential next-generation approaches to TPD, from monovalent protein degraders to molecular glues to novel E3 ligases. With partners, and on its own, the company is developing TPD drugs to fight cancer, central nervous system diseases, and other conditions.
In The Media
Explore Companies
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors